Ovarian hyperstimulation syndrome: Facts and fallacies

Obstetrical and Gynecological Survey

Volumn 53, Issue 7, 1998, Pages 439-449

  Beerendonk, C C M ^a   Van Dop, P A ^a   Braat, D D M ^a   Merkus, J M W M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN; ENDOTHELIN 1; ESTROGEN; GONADORELIN AGONIST; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; LUTEINIZING HORMONE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

BED REST; CAPILLARY PERMEABILITY; CLINICAL FEATURE; CONCEPTION; DISEASE CLASSIFICATION; EARLY DIAGNOSIS; FLUID THERAPY; HUMAN; INFERTILITY THERAPY; OVARY DISEASE; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PARACENTESIS; PATHOGENESIS; PATIENT MONITORING; PREGNANCY TERMINATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR;

ALGORITHMS; CAPILLARY PERMEABILITY; DECISION TREES; FEMALE; FLUID SHIFTS; HEMODYNAMIC PROCESSES; HUMANS; INCIDENCE; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; PRIMARY PREVENTION; RISK FACTORS;

EID: 0031816835     PISSN: 00297828     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006254-199807000-00024     Document Type: Review

References (101)

1. Cluroe AD, Synek BJ. A fatal case of ovarian hyperstimulation syndrome with cerebral infarction. Pathology 1995;27:344-346.
2. Golan A, Ron-El R, Herman A et al. Ovarian hyperstimulation syndrome: An update review. Obstet Gynecol Surv 1989;44: 430-440.
3. Rabau E, David A, Serr DM et al. Human menopausal gonadotropins for anovulation and sterility. Am J Obstet Gynecol 1967;98:92-98.
4. Schenker JG, Weinstein D. Ovarian hyperstimulation syndrome: A current survey. Fertil Steril 1978;30:255-268.
5. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: Prevention and treatment. Fertil Steril 1992;58:249-261.
6. Merkus JMWM, Bots RSGM, Peeters MF et al. Het ovarium-hyperstimulatiesyndroom. Ned Tijdschr Geneeskd 1990;134: 944-946.
7. McArdle C, Seibel M, Hann LE et al. The diagnosis of ovarian hyperstimulation (OHS): The impact of ultrasound. Fertil Steril 1983;39:464-467.
8. Dahl Lyons CA, Wheeler CA, Frishman GN et al. Early and late presentation of the ovarian hyperstimulation syndrome: Two distinct entities with different risk factors. Hum Reprod 1994; 9:792-799.
9. Waterstone JJ, Summers BA, Hoskins MC et al. Ovarian hyperstimulation syndrome and deep cerebral venous thrombosis. Br J Obstet Gynaecol 1992;99:439-440.
10. Germond M, Wirthner D, Thorin D et al. Aorto-subclavian thromboembolism: A rare complication associated with moderate ovarian hyperstimulation syndrome. Hum Reprod 1996; 11:1173-1176.
11. Zosmer A, Katz Z, Lancet M et al. Adult respiratory distress syndrome complicating ovarian hyperstimulation syndrome. Fertil Steril 1987;47:524-526.
12. Chin NW, Friedman CI, Awadalla SG et al. Adnexal torsion as a complication of superovulation for ovum retrieval. Fertil Steril 1987;48:149-151.
13. Paulson RJ, Lobo RA. Ovarian hyperstimulation complicating the clinical presentation of a pre-existing ectopic pregnancy. Fertil Steril 1988;50:670-671.
14. Moosburger D, Tews G. Severe ovarian hyperstimulation syndrome and combined intrauterine and tubal pregnancy after in vitro fertilization and embryo transfer. Hum Reprod 1996;11: 68-69.
15. Coccia ME, Bracco GL, Cattaneo A et al. Massive vulvar edema in ovarian hyperstimulation syndrome: A case report. J Reprod Med 1995;40:659-660.
16. Wakim AN, Fox SD. Elevated liver function tests in a case of moderate ovarian hyperstimulation syndrome. Hum Reprod 1996;11:588-589.
17. Kingsland CR, Collins JV, Rizk B et al. Ovarian hyperstimulation presenting as acute hydrothorax after in vitro fertilization. Am J Obstet Gynecol 1989;161:381-382.
18. Bassil S, Da Costa S, Toussaint-Demylle D et al. A unilateral hydrothorax as the only manifestation of ovarian hyperstimulation syndrome: A case report. Fertil Steril 1996;66:1023-1025.
19. Loret de Mola JR, Arredondo-Soberon F, Randle CP et al. Markedly elevated cytokines in pleural effusion during the ovarian hyperstimulation syndrome: Transudate or ascites? Fertil Steril 1997;67:780-782.
20. Shapiro AG, Thomas T, Epstein M. Management of hyperstimulation syndrome. Fertil Steril 1977;28:237-239.
21. Navot D, Relou A, Birkenfeld A et al. Risk factors and prognostic variables in the ovarian hyperstimulation syndrome. Am J Obstet Gynecol 1988;159:210-215.
22. Mizunuma H, Andoh K, Yamada K et al. Prediction and prevention of ovarian hyperstimulation by monitoring endogenous luteinizing hormone release during purified follicle-stimulating hormone therapy. Fertil Steril 1992;58:46-50.
23. Buyalos RP, Lee CT. Polycystic ovary syndrome: Pathophysiology and outcome with in vitro fertilization. Fertil Steril 1996; 65:1-10.
24. Braat DDM, Schoemaker R, Schoemaker J. Life table analysis of fecundity in intravenously gonadotropin-releasing hormone-treated patients with normogonadotropic and hypogonadotropic amenorrhea. Fertil Steril 1991;55:266-271.
25. Forman RG, Frydman R, Egan D et al. Severe ovarian hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization: A European series and a proposal for prevention. Fertil Steril 1990;53:502-508.
26. MacDougall MJ, Tan SL, Jacobs HS. In vitro fertilization and the ovarian hyperstimulation syndrome. Hum Reprod 1992;7: 597-600.
27. Hughes E, Collins J, Vandekerckhove P. Ovulation induction with urinary follicle stimulating hormone vs human menopausal gonadotropin for clomiphene-resistant polycystic ovary syndrome. In: Lilford R, Hughes E, Vandekerckhove P, eds. Subfertility Module of The Cochrane Database of Systematic Reviews, [updated 06 September 1996]. Available in The Cochrane Library [database on disk and CDROM]. The Cochrane Collaboration; Issue 3. Oxford: Update Software; 1996. Updated quarterly. Available from: BMJ Publishing Group, London.
28. R) in infertile women pituitary-suppressed with triptorelin undergoing in vitro fertilization: A prospective, randomized, assessor-blind, multicentre trial. Hum Reprod 1995;10:3102-3106.
29. Out HJ, Mannaerts BMJL, Driessen SGAJ et al. A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle-stimulating hormone (Puregon vs. Metrodin) in in vitro fertilization. Hum Reprod 1995;10: 2534-2540.
30. Buvat J, Marcolin G, Guittard C et al. Luteal support after luteinizing hormone-releasing hormone agonist for in vitro fertilization: Superiority of human chorionic gonadotropin over oral progesterone. Fertil Steril 1990;53:490-494.
31. Smitz J, Devroey P, Braeckmans P et al. Management of failed cycles in an IVF/GIFT programme with the combination of a GnRH analogue and HMG. Hum Reprod 1987;2:309-314.
32. Herman A, Ron-El R, Golan A et al. Pregnancy rate and ovarian hyperstimulation after luteal human chorionic gonadotropin in in vitro fertilization stimulated with gonadotropin-releasing hormone analog and menotropins. Fertil Steril 1990; 53:92-96.
33. Haning RV, Austin CW, Carlson IH et al. Plasma estradiol is superior to ultrasound and urinary estriol glucuronide as a predictor of ovarian hyperstimulation during induction of ovulation with menotropins. Fertil Steril 1983;40:31-36.
34. Shalev E, Giladi Y, Matilsky M et al. Decreased incidence of severe ovarian hyperstimulation syndrome in high-risk in vitro fertilization patients receiving intravenous albumin: A prospective study. Hum Reprod 1995;10:1373-1376.
35. Revel A, Barak V, Lavy Y et al. Characterization of intraperitoneal cytokines and nitrites in women with severe ovarian hyperstimulation syndrome. Fertil Steril 1996;66:66-71.
36. Tollan A, Holst N, Forsdahl F et al. Transcapillary fluid dynamics during ovarian stimulation for in vitro fertilization. Am J Obstet Gynecol 1990;162:554-558.
37. Polishuk WZ, Schenker JG. Ovarian overstimulation syndrome. Fertil Steril 1969;20:443-450.
38. Borenstein R, Elhalah U, Lunenfeld B et al. Severe ovarian hyperstimulation syndrome: A reevaluated therapeutic approach. Fertil Steril 1989;51:791-795.
39. Haning RV, Strawn EY, Nolten WE. Pathophysiology of the ovarian hyperstimulation syndrome. Obstet Gynecol 1985;66: 220-224.
40. Goldsman MP, Pedram A, Dominguez CE et al. Increased capillary permeability induced by human follicular fluid: A hypothesis for an ovarian origin of the hyperstimulation syndrome. Fertil Steril 1995;63:268-272.
41. McClure N, Healy, DL, Rogers PAW et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 1994;344:235-236.
42. Blankestijn PJ, Derkx FHM, Van Geelen JA et al. Increase in plasma prorenin during the menstrual cycle of a bilaterally nephrectomized woman. Br J Obstet Gynaecol 1990;97: 1038-1042.
43. Itskovitz J, Bruneval P, Soubrier F et al. Localization of renin gene expression to monkey ovarian theca cells by in situ hybridization. J Clin Endocrinol Metab 1992;75:1374-1380.
44. Paulson RJ, Do YS, Hsueh WA et al. Ovarian renin production in vitro and in vivo: Characterization and clinical correlation. Fertil Steril 1989;51:634-638.
45. Lightman A, Tarlatzis BC, Rzasa PJ et al. The ovarian renin-angiotensin system: Renin-like activity and angiotensin II/III immunoreactivity in gonadotropin-stimulated and unstimulated human follicular fluid. Am J Obstet Gynecol 1987;156: 808-816.
46. Itskovitz J, Sealey JE. Ovarian prorenin-renin-angiotensin system. Obstet Gynecol Surv 1987;42:545-551.
47. Derkx FHM, Stuenkel C, Schalekamp MPA et al. Immunoreactive renin, prorenin, and enzymatically active renin in plasma during pregnancy and in women taking oral contraceptives. J Clin Endocrinol Metab 1986;63:1008-1015.
48. Glorioso N, Atlas SA, Laragh JH et al. Prorenin in high concentrations in human ovarian follicular fluid. Science 1986; 233:1422-1424.
49. Derkx FHM, Alberda AT, Zeilmaker GH et al. High concentrations of immunoreactive renin, prorenin and enzymatically active renin in human ovarian follicular fluid. Br J Obstet Gynaecol 1987;94:4-9.
50. Sealey JE, Glorioso N, Itskovitz J et al. Prorenin as a reproductive hormone. New form of the renin system. Am J Med 1986;81:1041-1046.
51. Itskovitz J, Rubattu S, Rosenwaks Z et al. Relationship of follicular fluid prorenin to oocyte maturation, steroid levels and outcome of in vitro fertilization. J Clin Endocrinol Metab 1991; 72:165-171.
52. Itskovitz J, Sealey JE, Glorioso N et al. Plasma prorenin response to human chorionic gonadotropin in ovarian-hyperstimulated women: Correlation with the number of ovarian follicles and steroid hormone concentrations. Proc Natl Acad Sci USA 1987;84:7285-7289.
53. Robertson AL, Khairallah PA. Effects of Angiotensin II and some analogues on vascular permeability in the rabbit. Circ Res 1972;31:923-931.
54. Fernandez LA, Twickler J, Mead A. Neovascularization produced by angiotensin II. J Lab Clin Med 1985;105:141-145.
55. Frederick JL, Shimanuki T, DiZerega GS. Initiation of angiogenesis by human follicular fluid. Science 1984;224:389-390.
56. Navot D, Margalioth DJ, Laufer N et al. Direct correlation between plasma renin activity and severity of the ovarian hyperstimulation syndrome. Fertil Steril 1987;48:57-61.
57. Ong ACM, Elsen V, Rennie DP et al. The pathogenesis of the ovarian hyperstimulation syndrome (OHS): A possible role for ovarian renin. Clin Endocrinol 1991;34:43-39.
58. Smith BH, Cooke ID. Ovarian hyperstimulation: Actual and theoretical risks. Minimise them by monitoring oestrogen concentration. Br Med J 1991;302:127-128.
59. Schenker JG, Polishuk WZ. The role of prostaglandins in ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol 1976;6:47-52.
60. Pride SM, Ho Yuen B et al. Relationship of gonadotropin-releasing hormone, danazol, and prostaglandin blockade to ovarian enlargement and ascites formation of the ovarian hyperstimulation syndrome in the rabbit. Am J Obstet Gynecol 1986;154:1155-1160.
61. Knox GEK. Antihistamine blockade of the ovarian hyperstimulation syndrome. Am J Obstet Gynecol 1974;118:992-994.
62. Zaidise I, Friedman M, Lindenbaum ES et al. Serotonin and the ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol 1983;15:55-60.
63. Pride SM, Ho Yuen B et al. Clinical, endocrinologic, and intraovarian prostaglandin F responses to H-1 receptor blockade in the ovarian hyperstimulation syndrome: Studies in the rabbit model. Am J Obstet Gynecol 1984;148:670-674.
64. Ho Yuen B, McComb P, Sy L et al. Plasma prolactin, human chorionic gonadotropin, estradiol, testosterone, and progesterone in the ovarian hyperstimulation syndrome. Am J Obstet Gynecol 1979;133:316-320.
65. Krasnow JS, Berga SL, Guzick DS et al. Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulation syndrome: A preliminary report. Fertil Steril 1996;65:552-555.
66. Schiff E, Alcalay M, Peleg E et al. Immunoreactive endothelins in human follicular fluid. Gynecol Obstet Invest 1993;36:12-14.
67. Kamada S, Kubota T, Taguchi M et al. High levels of immunoreactive endothelin-1 in human follicular fluids. Hum Reprod 1993;8:674-677.
68. Usuki S, Saitoh T, Suzuki N et al. Endothelin-1 and endothelin-3 stimulate ovarian steroidogenesis. J Cardiovasc Pharmacol 1991;17:S256-259.
69. Kubota T, Kamada S, Hirata Y et al. Synthesis and release of endothelin-1 by human decidual cells. J Clin Endocrinol Metab 1992;75:1230-1234.
70. Balasch J, Arroyo V, Fabregues F et al. Immunoreactive endothelin plasma levels in severe ovarian hyperstimulation syndrome. Fertil Steril 1995;64:65-68.
71. McClure N, Healy DL, Rogers PAW et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 1994;344:235-236.
72. Abramov Y, Barak V, Nisman B et al. Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. Fertil Steril 1997; 67:261-265.
73. Abramov Y, Schenker JG, Lewin A et al. Plasma inflammatory cytokines correlate to the ovarian hyperstimulation syndrome. Hum Reprod 1996;11:1381-1386.
74. Blankstein J, Shalev J, Saadon T et al. Ovarian hyperstimulation syndrome: Prediction by number and size of preovulatory ovarian follicles. Fertil Steril 1987;47:597-602.
75. Aurousseau MH, Samama MM, Belhassen A et al. Risk of thromboembolism in relation to an in-vitro fertilization programme: Three case reports. Hum Reprod 1995;10:94-97.
76. Balasch J, Reverter JC, Fabregues F et al. Increased induced monocyte tissue factor expression by plasma from patients with severe ovarian hyperstimulation syndrome. Fertil Steril 1996;66:608-613.
77. Kodama H, Fukuda J, Karube H et al. Status of the coagulation and fibrinolytic systems in ovarian hyperstimulation syndrome. Fertil Steril 1996;66:417-424.
78. Kodama H, Fukuda J, Karube H et al. Characteristics of blood hemostatic markers in a patient with ovarian hyperstimulation syndrome who actually developed thromboembolism. Fertil Steril 1995;64:1207-1209.
79. Jäger W, Diedrich K, Wildt L. Elevated levels of CA-125 in serum of patients suffering from ovarian hyperstimulation syndrome. Fertil Steril 1987;48:675-678.
80. Aboulghar MA, Mansour RT, Serour GI et al. Follicular aspiration does not protect against the development of ovarian hyperstimulation syndrome. J Assist Reprod Genet 1992;9: 238-43.
81. Delvigne A, Dubois M, Battheu B et al. The ovarian hyperstimulation syndrome in in-vitro fertilization: A Belgian multicentric study. II. Multiple discriminant analysis for risk prediction. Hum Reprod 1993;8:1361-1366.
82. Scheele F, Hompes PGA, Bernardus RE et al. Severe ovarian hyperstimulation: A case report and essentials of prevention and management. Eur J Obstet Gynecol Reprod Biol 1992; 45:187-192.
83. Urman B, Pride SM, Ho Yuen B. Management of overstimulated gonadotrophin cycles with a controlled drift period. Hum Reprod 1992;7:213-217.
84. Benadiva CA, Davis O, Kligman I et al. Withholding gonadotropin administration is an effective alternative for the prevention of ovarian hyperstimulation syndrome. Fertil Steril 1997; 67:724-727.
85. Itskovitz J, Boldes R, Levron J et al. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertil Steril 1991;56:213-220.
86. Lewit N, Kol S, Manor D et al. Comparison of gonadotrophin-releasing hormone analogues and human chorionic gonadotrophin for the induction of ovulation and prevention of ovarian hyperstimulation syndrome: A case-control study. Hum Reprod 1996;11:1399-1402.
87. Trounson A, Wood C, Kausche A. In vitro maturation and the fertilization and developmental competence of oocytes recovered from untreated polycystic ovarian patients. Fertil Steril 1994;62:353-362.
88. Jaroudi KA, Hollanders JMG, Sieck UV et al. Pregnancy after transfer of embryos which were generated from in vitro matured oocytes. Hum Reprod 1997;12:857-859.
89. Asch RH, Ivery G, Goldsman M et al. The use of intraveous albumin in patients at high risk for severe ovarian hyperstimulation syndrome. Hum Reprod 1993;8:1015-1020.
90. Shoham Z, Weissman A, Barash A et al. Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an in vitro fertilization program: A prospective, randomized, placebo-controlled study. Fertil Steril 1994;62:137-142.
91. Shaker AG, Zosmer A, Dean N et al. Comparison of intravenous albumin and transfer of fresh embryos with cryopreservation of all embryos for subsequent transfer in prevention of ovarian hyperstimulation syndrome. Fertil Steril 1996;65:992-996.
92. Lewit N, Kol S, Ronene N et al. Does intravenous administration of human albumin prevent severe ovarian hyperstimulation syndrome? Fertil Steril 1996;66:654-656.
93. Ng E, Leader A, Claman P et al. Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome in an in-vitro fertilization programme. Hum Reprod 1995;10:807-810.
94. Amso NN, Ahuja KK, Morris N et al. The management of predicted ovarian hyperstimulation involving gonadotropin-releasing hormone analog with elective cryopreservation of all pre-embryos. Fertil Steril 1990;53:1087-1090.
95. Balasch J, Arroy V, Carmona F et al. Severe ovarian hyperstimulation syndrome: Role of peripheral vasodilation. Fertil Steril 1991;56:1077-1082.
96. Aboulghar MA, Mansour RT, Serour GI et al. Ultrasonically guided vaginal aspiration of ascites in the treatment of severe hyperstimulation syndrome. Fertil Steril 1990;53:933-935.
97. Aboulghar MA, Mansour RT, Serour GI et al. Autotransfusion of the ascitic fluid in the treatment of severe ovarian hyperstimulation syndrome. Fertil Steril 1992;5:1056-1059.
98. Beck DH, Massey S, Taylor BL et al. Continuous ascitic recirculation in severe ovarian hyperstimulation syndrome. Intensive Care Med 1995;21:590-593.
99. Fakih H, Bello S. Ovarian cyst aspiration: A therapeutic approach to ovarian hyperstimulation syndrome. Fertil Steril 1992;58:829-832.
100. Tan SL, Balen A, Hussein EE et al. The administration of glucocorticoids for the prevention of ovarian hyperstimulation syndrome in in vitro fertilization: A prospective randomized study. Fertil Steril 1992;58:378-383.
101. Morris RS, Wong IL, Kirkman E et al. Inhibition of ovarian-derived prorenin to angiotensin cascade in the treatment of ovarian hyperstimulation syndrome. Hum Reprod 1995;10: 1355-1358.